Literature DB >> 3834229

Acid-base homeostasis during chronic PTH excess in humans.

H N Hulter, J C Peterson.   

Abstract

The chronic renal and systemic acid-base effects of hyperparathyroidism in humans remain controversial and unresolved. The present studies evaluated the acid-base response of normal human subjects to a 13-day intravenous infusion of synthetic b(1-34) PTH sufficient to result in sustained hypercalcemia and hypophosphatemia. The acid-base response was biphasic: an initial transient renal acidosis developed on the first day of PTH infusion, followed by a prompt increase in net acid excretion and plasma [HCO3-] of sufficient magnitude to result in a steady state of mild metabolic alkalosis. The results indicate that: 1) sustained, continuous, experimentally produced hyperparathyroidism results in a steady state of mild metabolic alkalosis; 2) the alkalosis is both generated and maintained, at least in part, by renal mechanisms; and 3) reported renal acidosis in sustained clinical conditions of primary hyperparathyroidism is not attributable to either direct or indirect effects of PTH excess when present for a 2-week period, an interval sufficient to re-establish a new steady state of renal and systemic acid-base equilibrium.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3834229     DOI: 10.1038/ki.1985.139

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  3 in total

1.  Distal renal tubular acidosis in primary hyperparathyroidism.

Authors:  Tom Edward Ngo Lo; Iris Thiele Isip Tan
Journal:  BMJ Case Rep       Date:  2015-01-29

2.  Acute metabolic acidosis enhances circulating parathyroid hormone, which contributes to the renal response against acidosis in the rat.

Authors:  M Bichara; O Mercier; P Borensztein; M Paillard
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

3.  Cyclic adenosine monophosphate acutely inhibits and chronically stimulates Na/H antiporter in OKP cells.

Authors:  A Cano; P Preisig; R J Alpern
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.